JAMA Oncology

Enlargement of Shoulder Muscles in an Older Man

A 70-year-old man with a history of hypertension and chronic migraine presented with 10 months of progressive generalized muscle weakness and stiffness. Physical examination revealed generalized muscle wasting except for hypertrophy of bilateral shoulder muscles, and a deltoid muscle biopsy…

Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs

Importance  Evidence-based treatment decisions for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) require individualized patient-centered decision-making that accounts for patient and cancer characteristics. Objective  To create an accessible guidance document to educate clinicians and patients on biomarkers informing prognosis and treatment in unresectable or…

Hairy Kidneys and Sclerotic Bone Lesions

A 72-year-old man with a history of polycythemia vera (positive for JAK2 V617F) presented with several months of functional decline and weight loss. An 18F-fluorodeoxyglucose positron emission tomography/computed tomography showed soft tissue infiltrates and sclerosis of the perirenal spaces with…

Advancing Global Pharmacoequity in Oncology

Importance  Limited availability and affordability of cancer drugs contribute to staggering disparities in cancer survival between high-income and low- and middle-income countries (LMICs). As infrastructure for cancer care rapidly develops, there is an urgent need to reduce prices and improve access…

Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy – A Review

Importance  The commercialization of chimeric antigen receptor–T-cell (CAR-T) therapy has changed the landscape of treatment of hematological cancers. Numerous studies from the early 2000s paved the way for cell-based targeted therapeutics, which have been established as practice-changing therapies in lymphoma, leukemia,…

Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer – The FAST Multidisciplinary Group Consensus Statement

Importance  BRAF/MEK inhibitors revolutionized the treatment of BRAF V600E-variant anaplastic thyroid carcinoma (BRAFv-ATC), offering improved outcomes for patients with this previously incurable disease. Observations  Anaplastic thyroid carcinoma (ATC) accounts for approximately half of thyroid cancer−related deaths. It presents as a rapidly growing tumor that…